Last reviewed · How we verify
NCT04586062
Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
trial testing Plasminogen in Ligneous Conjunctivitis. Available.
Quick facts
| Lead sponsor | Kedrion S.p.A. |
|---|---|
| Status | AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Plasminogen — full drug profile →
Conditions studied
- Ligneous Conjunctivitis — all drugs for Ligneous Conjunctivitis →
Sponsor
Kedrion S.p.A. — full company profile →
Who can join
Eligibility, any sex, with Ligneous Conjunctivitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Long-term follow-up in a pediatric patient with Ligneous Conjunctivitis due to PLG gene mutation in topical plasminogen treatment after successful use of ocular prosthesis for aesthetic rehabilitation: a case report.
Panfili FM, Valente P, Ficari A, Cortellessa F, et al · · 2023 · PMID 37612758 · DOI 10.1186/s13052-023-01503-x
Verify or expand the search:
- PubMed search for NCT04586062
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Plasminogen
Trials testing the same drug.
- NCT06381661 — Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Tra · Phase 2 · not yet recruiting
Other Kedrion S.p.A. trials
Trials by the same sponsor.
- NCT04944979 — Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) · Phase 3 · active not recruiting
- NCT03961009 — Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients · Phase 3 · completed
- NCT01531803 — Safety Study of Kedbumin 25% Versus Normal Saline in the Treatment of Post-Surgical Hypovolemia in Pediatric Patients · Phase 4 · terminated
- NCT01554956 — Efficacy/Safety of Human Plasminogen Eye Drop in Ligneous Conjunctivitis Patients · Phase 2, PHASE3 · completed
- NCT01581593 — Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04586062 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kedrion S.p.A.
- Last refreshed: 5 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04586062.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing